Completed PHASE1 INTERVENTIONAL 1-arm NCT00676949

Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors (peptidevac)

Phase I Study of Tumor Specific Potentiated Vaccine Therapy Using Cyclophosphamide Combined Epitope Peptide Cocktail for Progressive/Relapsed Solid Tumors(GI/Lung/Cervical Cancer)

Sponsor: Human Genome Center, Institute of Medical Science, University of Tokyo

Conditions Metastatic Tumors

Interventions 5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1

Updated 5 times since 2017 Last updated: Jun 22, 2011 Started: Nov 30, 2007 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00676949, this PHASE1 trial focuses on Metastatic Tumors and remains completed. Sponsored by Human Genome Center, Institute of Medical Science, University of Tokyo, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Human Genome Center, Institute of Medical Science, University of Tokyo
Kyushu University

Data source: Kyushu University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fukuoka, Japan